Originally published as JCO Early Release 10.1200/JCO.2005.07.100 on July 11 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kemeny, N. Articles by Fong, Y. Search for Related Content PubMed PubMed Citation Articles by Kemeny, N. Articles by Fong, Y. Related Articles Related Editorial Social Bookmarking                            What's this?

Phase I Trial of Systemic Oxaliplatin Combination Chemotherapy With Hepatic Arterial Infusion in Patients With Unresectable Liver Metastases From Colorectal Cancer

From the Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY

Address reprint requests to Nancy E. Kemeny, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: kemenyn{at}mskcc.org

PURPOSE: To determine the maximum-tolerated dose (MTD) of concurrent systemic oxaliplatin (Oxal) combinations plus hepatic arterial infusion (HAI) in patients with unresectable hepatic metastases from colorectal cancer.

PATIENTS AND METHODS: Thirty-six patients (89% previously treated) with unresectable liver metastases were treated with concurrent HAI and systemic Oxal plus irinotecan (CPT-11; group A) or Oxal, fluorouracil (FU), and leucovorin (LV; group B). Systemic chemotherapy was administered every 2 weeks concurrent with 2 weeks of HAI floxuridine (FUDR) and dexamethasone (Dex) every 28 days.

RESULTS: The MTD for patients in group A was Oxal 100 mg/m², CPT-11 150 mg/m², and FUDR 0.12 mg/kg x 30 mL divided by pump flow rate. The MTD for group B was Oxal 100 mg/m², LV 400 mg/m², and FU 1,400 mg/m² by continuous infusion over 48 hours, with the same FUDR dose as in group A. Grade 3 or 4 toxicities in groups A and B included diarrhea (24% and 20%), neutropenia (10% and 7%), neurotoxicity (24% and 20%), and bilirubin more than 3 mg/mL (5% and 7%, respectively). The complete and partial response rate totaled 90% for group A and 87% for group B. Median survival time was 36 and 22 months for groups A and B, respectively. Seven patients in group A were ultimately able to undergo liver resection.

CONCLUSION: Combination therapy with HAI FUDR and Dex plus systemic Oxal combinations may be safely administered to patients with colorectal cancer. The high response rate (88%) and the possibility of conversion to resectability, despite disease progression on prior systemic regimens, suggest that these combinations should be evaluated in larger studies as first- or second-line therapy in patients with hepatic metastases from colorectal cancer.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• A Role for Hepatic-Directed Chemotherapy in Colorectal Liver Metastases
  William D. Ensminger
  JCO 2005 23: 4815-4817 [Full Text]

This article has been cited by other articles:

				N. Kemeny, M. Capanu, M. D'Angelica, W. Jarnagin, D. Haviland, R. Dematteo, and Y. Fong Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer Ann. Onc., July 1, 2009; 20(7): 1236 - 1241. [Abstract] [Full Text] [PDF]

				W. R. Jarnagin, L. H. Schwartz, D. H. Gultekin, M. Gonen, D. Haviland, J. Shia, M. D'Angelica, Y. Fong, R. DeMatteo, A. Tse, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival Ann. Onc., June 2, 2009; (2009) mdp029v1. [Abstract] [Full Text] [PDF]

				D. G. Power and N. E. Kemeny The role of floxuridine in metastatic liver disease Mol. Cancer Ther., May 1, 2009; 8(5): 1015 - 1025. [Abstract] [Full Text] [PDF]

				J. R. Bertino Implantable Pump For Long-Term Chemotherapy Administration Via the Hepatic Artery: Has It Fulfilled Its Promise? J. Clin. Oncol., October 1, 2008; 26(28): 4528 - 4529. [Full Text] [PDF]

				C. Pulitano, M. Arru, M. Catena, E. Guzzetti, G. Vitali, M. Ronzoni, M. Venturini, E. Villa, G. Ferla, and L. Aldrighetti Results of Preoperative Hepatic Arterial Infusion Chemotherapy in Patients Undergoing Liver Resection for Colorectal Liver Metastases Ann. Surg. Oncol., June 1, 2008; 15(6): 1661 - 1669. [Abstract] [Full Text] [PDF]

				M. D'Angelica, Y. Fong, R. P. DeMatteo, and W. R. Jarnagin Hepatic Arterial Infusion Chemotherapy for Metatstases From Colorectal Cancer: Is It Really the End of an Era? J. Clin. Oncol., June 1, 2008; 26(16): 2788 - 2789. [Full Text] [PDF]

				D. G. Power and G. D. Leonard Hepatic Arterial Infusion: A Treatment at the "End of an Era"? J. Clin. Oncol., May 20, 2008; 26(15): 2597 - 2598. [Full Text] [PDF]

				B. C. Pestalozzi, S. Gruttadauria, and P.-A. Clavien Hepatic Arterial Infusion: The Beginning of the Combination Era J. Clin. Oncol., May 1, 2008; 26(13): 2231 - 2232. [Full Text] [PDF]

				S. Mocellin, P. Pilati, and D. Nitti In Reply J. Clin. Oncol., May 1, 2008; 26(13): 2232 - 2233. [Full Text] [PDF]

				G. Galizia, E. Lieto, M. Orditura, P. Castellano, V. Imperatore, M. Pinto, and A. Zamboli First-Line Chemotherapy vs Bowel Tumor Resection Plus Chemotherapy for Patients With Unresectable Synchronous Colorectal Hepatic Metastases Arch Surg, April 1, 2008; 143(4): 352 - 358. [Abstract] [Full Text] [PDF]

				B. Sandoval and Y. Fong Adjuvant Therapy after Resection of Hepatic Colorectal Metastases Ann. Surg. Oncol., January 1, 2008; 15(1): 9 - 10. [Full Text] [PDF]

				V. Boige, D. Malka, D. Elias, M. Castaing, T. De Baere, D. Goere, C. Dromain, M. Pocard, and M. Ducreux Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure Ann. Surg. Oncol., January 1, 2008; 15(1): 219 - 226. [Abstract] [Full Text] [PDF]

				H. Seki, T. Ozaki, and M. Shiina Side-Hole Catheter Placement for Hepatic Arterial Infusion Chemotherapy in Patients with Liver Metastases from Colorectal Cancer: Long-Term Treatment and Survival Benefit Am. J. Roentgenol., January 1, 2008; 190(1): 111 - 120. [Abstract] [Full Text] [PDF]

				S. Mocellin, P. Pilati, M. Lise, and D. Nitti Meta-Analysis of Hepatic Arterial Infusion for Unresectable Liver Metastases From Colorectal Cancer: The End of an Era? J. Clin. Oncol., December 10, 2007; 25(35): 5649 - 5654. [Abstract] [Full Text] [PDF]

				H. Z. Malik, S. Farid, A. Al-Mukthar, A. Anthoney, G. J. Toogood, J. P. A. Lodge, and K. R. Prasad A Critical Appraisal of the Role of Neoadjuvant Chemotherapy for Colorectal Liver Metastases: A Case-Controlled Study Ann. Surg. Oncol., December 1, 2007; 14(12): 3519 - 3526. [Abstract] [Full Text] [PDF]

				D. J. Gallagher, M. Capanu, G. Raggio, and N. Kemeny Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis Ann. Onc., December 1, 2007; 18(12): 1995 - 1999. [Abstract] [Full Text] [PDF]

				T. Liersch, J. Meller, M. Bittrich, B. Kulle, H. Becker, and D. M. Goldenberg Update of Carcinoembryonic Antigen Radioimmunotherapy with 131I-Labetuzumab After Salvage Resection of Colorectal Liver Metastases: Comparison of Outcome to a Contemporaneous Control Group Ann. Surg. Oncol., September 1, 2007; 14(9): 2577 - 2590. [Abstract] [Full Text] [PDF]

				N. Kemeny Presurgical Chemotherapy in Patients Being Considered for Liver Resection Oncologist, July 1, 2007; 12(7): 825 - 839. [Abstract] [Full Text] [PDF]

				M. D'Angelica, P. Kornprat, M. Gonen, K.-Y. Chung, W. R. Jarnagin, R. P. DeMatteo, Y. Fong, N. Kemeny, L. H. Blumgart, and L. B Saltz Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study Ann. Surg. Oncol., February 1, 2007; 14(2): 759 - 765. [Abstract] [Full Text] [PDF]

				D. L. Bartlett, J. Berlin, G. Y. Lauwers, W. A. Messersmith, N. J. Petrelli, and A. P. Venook Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement Ann. Surg. Oncol., October 1, 2006; 13(10): 1284 - 1292. [Full Text] [PDF]

				N. E. Kemeny, D. Niedzwiecki, D. R. Hollis, H.-J. Lenz, R. S. Warren, M. J. Naughton, J. C. Weeks, E. R. Sigurdson, J. E. Herndon II, C. Zhang, et al. Hepatic Arterial Infusion Versus Systemic Therapy for Hepatic Metastases From Colorectal Cancer: A Randomized Trial of Efficacy, Quality of Life, and Molecular Markers (CALGB 9481) J. Clin. Oncol., March 20, 2006; 24(9): 1395 - 1403. [Abstract] [Full Text] [PDF]

				M. M. Kemeny Expressing the Surgery First Position on Treatment of Synchronous Colorectal Metastases in the Asymptomatic Patient Ann. Surg. Oncol., February 1, 2006; 13(2): 140 - 141. [Full Text] [PDF]

				G. Chong and D. Cunningham Improving Long-Term Outcomes for Patients With Liver Metastases From Colorectal Cancer J. Clin. Oncol., December 20, 2005; 23(36): 9063 - 9066. [Full Text] [PDF]

				W. D. Ensminger A Role for Hepatic-Directed Chemotherapy in Colorectal Liver Metastases J. Clin. Oncol., August 1, 2005; 23(22): 4815 - 4817. [Full Text] [PDF]